Menu ×

HEALTHCARE & PHARMACEUTICALDISCOUNT VALID TILL 31st-JANUARY , 2022

Cutaneous T-cell Lymphoma Treatment Market Segmentation by Type (Mycosis Fungoides [MF], Sézary Syndrome, Others); by Treatment (Tropical Therapy, Radiation Therapy, Chemotherapy, Immunotherapy, and Others); by End-User (Hospitals, Clinics, Ambulatory Surgical Centers, and Others) – Global Demand Analysis & Opportunity Outlook 2030

  • Text Size:

Extensive insights into the Growth of Cutaneous T-cell Lymphoma Treatment Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More

IN THE NEWS

  • October 2021: Kyowa Kirin Co., announced a new study of real world data that showed higher response rates in patients with CTCL who are treated with their mogamulizumab drug, POTELIGEO. This study was the pivotal Phase 3 trial that investigated treatment with POTELIGEO.

  • March 2021: Eisai Co., Ltd. obtained marketing and manufacturing  approval for the anticancer agent, Remitoro, in Japan for patients with relapsed or refractory PTCL or CTCL. Remitoro has been considered as a drug with high medical need.

Global Cutaneous T-cell Lymphoma Treatment Market Highlights Over 2022 – 2030

The global cutaneous T-cell lymphoma treatment market is estimated to garner significant revenue by growing at a CAGR of ~5% over the forecast period, i.e., 2022 – 2030. The growth of the market is attributed to rising prevalence of lymphoma cancer and growing geriatric population. Moreover, growing advances in cancer treatments, and increasing R&D activities and investments for novel treatment options are further fostering the growth of the market.

Cutaneous T-cell Lymphoma Treatment Market Graph

Cutaneous T-cell lymphoma (CTCL) is a rare type of cancer of the T lymphocytes, a type of white blood cell which help body’s germ-fighting immune system. CTCL mainly affects the skin but may also affect blood, lymph nodes, and/or internal organs in advance stages. It is one of the most uncommon types of non-Hodgkin lymphoma.

However, high cost and long duration of treatment, lack of proper detection technique, and lack of awareness about the symptoms and treatment of cutaneous T-cell lymphoma are likely to restrain the growth of the market. Furthermore, treatments like chemotherapy have substantial side effects on health. This factor is also likely to hinder the market growth.

The market is segmented by type into mycosis fungoides (MF), sézary syndrome, and others, out of which, the mycosis fungoides segment is anticipated to hold the largest market share on the back of being the most common type of CTCL, constituting over 50% of all cases. It is also easier to diagnose and about 70 to 80 percent patients are diagnosed at early stages.

On the basis of treatment, the market is segmented into tropical therapy, radiation therapy, chemotherapy, immunotherapy, and others, out of which, the tropical therapy segment is estimated hold the largest market share owing to growing approvals and larger adoption of tropical drugs for the treatment.CLICK TO DOWNLOAD SAMPLE REPORT

Major Macro-Economic Indicators Impacting the Market Growth

Healthcare Graph

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Cutaneous T-cell Lymphoma Treatment Market Regional Synopsis

Geographically, the global cutaneous T-cell lymphoma treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. North America is expected to hold the largest market share owing to high prevalence of CTCL in the region and surge in the demand for progressive treatment options and early adoption of new technologies. About 3,000 new cases of CTCL are seen in the U.S. every year.

Asia-Pacific region is projected to witness growth at the highest rate over the forecast period owing to growing improvements in healthcare sector, developments for detection and diagnosis of rare diseases, and presence of a diverse patient structure.

Cutaneous T-cell Lymphoma Treatment Market Share Graph

The global cutaneous T-cell lymphoma treatment market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook

Market Segmentation

Our in-depth analysis of the global cutaneous T-cell lymphoma treatment market includes the following segments:

By Type

  • Mycosis Fungoides (MF)
  • Sézary Syndrome
  • Others

By Treatment

  • Tropical Therapy
  • Radiation Therapy
  • Chemotherapy
  • Immunotherapy
  • Others

By End-User

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Others

Growth Drivers

  • Rising prevalence of lymphoma cancer and growing geriatric population
  • Advances in cancer treatments
  • Increasing R&D activities and investments

Challenges

  • High cost and long duration of treatment
  • Lack of proper detection technique
  • Lack of awareness about the symptoms and treatment

Top Featured Companies Dominating the Market

  • Soligenix 
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis 
  • Bausch Health Companies Inc.
  • Kyowa Kirin Co., Ltd.
  • Bristol-Myers Squibb Company
  • Merck & Co.
  • Helsinn Healthcare SA
  • Elorac
  • Eisai Co., Ltd.
  • Seagen Inc.

FREQUENTLY ASKED QUESTIONS


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved